IDEAYA Biosciences (IDYA) EBITDA (2018 - 2026)

IDEAYA Biosciences has disclosed EBITDA across 9 years of filings, most recently posting -$101.3 million for Q1 2026.

• EBITDA for Q1 2026 came in at -$101.3 million, down 41.87% year-over-year; the trailing twelve-month figure through Mar 2026 was -$142.1 million (up 53.33% YoY), and the FY2025 annual result was -$112.2 million, up 59.07% from the prior year.
• EBITDA came in at -$101.3 million for Q1 2026 at IDEAYA Biosciences, down from -$83.1 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $119.8 million in Q3 2025 to a low of -$133.3 million in Q4 2024.
• The 5-year median for EBITDA is -$32.6 million (2023), against an average of -$38.7 million.
• Across the five-year window, EBITDA sank 2274.8% in 2023 and jumped 357.2% in 2025, its largest moves.
• IDEAYA Biosciences' EBITDA stood at -$23.1 million in 2022, then slumped by 41.5% to -$32.6 million in 2023, then tumbled by 308.47% to -$133.3 million in 2024, then surged by 37.71% to -$83.1 million in 2025, then slipped by 21.96% to -$101.3 million in 2026.
• The last three EBITDA figures came in at -$101.3 million (Q1 2026), -$83.1 million (Q4 2025), and $119.8 million (Q3 2025), per Business Quant data.